Strides Shasun gets USFDA nod for anti-HIV drug Abacavir
- Tata Motors stops production of Indica, Indigo CS
- Healthcare, energy farm, smart cities seen boosting 5G demand
- 5G to offer $27 billion opportunity for India by 2026: Ericsson
- Hyundai to hike vehicle prices by up to 2% from June, no change in new Creta prices
- US eyes India’s dairy market, seeks to pull sops to textiles industry
Hyderabad: Strides Shasun Ltd on Tuesday said it got approval from US Food and Drug Administration (USFDA) for anti-retroviral Abacavir tablets used in the treatment of patients with HIV infection.
Strides said the US approval is for 300 mg dosage form.
The product will be manufactured at the company’s USFDA approved facility at Bengaluru and marketed by Strides in the US market, the company said in a statement.
“The product will be launched immediately,” it added.
According to IMS sales data, the US market for Abacavir is approximately $30 million.
Shares of Strides rose 1.31% to close at Rs1,056.70 on BSE, while the benchmark Sensex declined 0.19% to 27,876.61 points.